{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:32:07Z","timestamp":1761993127387,"version":"build-2065373602"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00520-016-3286-z","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T10:21:36Z","timestamp":1464949296000},"page":"4487-4493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis"],"prefix":"10.1007","volume":"24","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guendalina","family":"Graffigna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Pungolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Pizzuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Falzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana Franca","family":"Capalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Intermesoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Melosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Capochiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Della","family":"Seta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Pacilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Mastrullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Trabacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester Maria","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u201353","journal-title":"Blood"},{"key":"3286_CR2","doi-asserted-by":"crossref","first-page":"abstr S677","DOI":"10.3324\/haematol.2013.091272","volume":"99","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, le Coutre PD, Jootar S et al (2014) ENESTnd 5-year follow-up: continued benefit of frontline nilotinib compared with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 99:abstr S677","journal-title":"Haematologica"},{"key":"3286_CR3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500","journal-title":"Blood"},{"issue":"suppl 5","key":"3286_CR4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.6004\/jnccn.2015.0207","volume":"13","author":"JP Radich","year":"2015","unstructured":"Radich JP (2015) Treatment milestones in chronic myelogenous leukemia: stay the course or change therapy? J Natl Compr Canc Netw 13(suppl 5):697\u2013699","journal-title":"J Natl Compr Canc Netw"},{"key":"3286_CR5","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554\u201360","journal-title":"Blood"},{"key":"3286_CR6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","volume":"39","author":"M Breccia","year":"2015","unstructured":"Breccia M, Efficace F, Sica S et al (2015) Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res 39:1055\u20131059","journal-title":"Leuk Res"},{"key":"3286_CR7","first-page":"3","volume-title":"Narrative based medicine: dialogue and discourse in clinical practice","author":"T Greenhalgh","year":"1998","unstructured":"Greenhalgh T, Hurwitz B (1998) Why study narrative? In: Greenhalgh T, Hurwitz B (eds) Narrative based medicine: dialogue and discourse in clinical practice. BMJ Books, London, pp 3\u201316"},{"key":"3286_CR8","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u201311","journal-title":"Blood"},{"key":"3286_CR9","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20138","journal-title":"J Clin Oncol"},{"key":"3286_CR10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N et al (2011) Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626\u201330","journal-title":"Leuk Res"},{"key":"3286_CR11","first-page":"115","volume":"300","author":"M Breccia","year":"2011","unstructured":"Breccia M, Efficace F, Alimena G (2011) Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? Leuk Res 300:115\u2013121","journal-title":"Leuk Res"},{"key":"3286_CR12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G et al (2012) Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107:904\u2013909","journal-title":"Br J Cancer"},{"issue":"S1","key":"3286_CR13","first-page":"453","volume":"98","author":"G Sharf","year":"2013","unstructured":"Sharf G, Hoffmann V, Bomabaci F et al (2013) Non-adherence in Chronic Myeloid Leukemia: Results of a global survey of 2546 CML patients in 79 countries. Haematologica 98(S1):453, abs. 104","journal-title":"Haematologica"},{"key":"3286_CR14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","volume":"38","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Cottone F et al (2014) Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res 38:294\u20138","journal-title":"Leuk Res"},{"key":"3286_CR15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","volume":"9","author":"M Kekale","year":"2015","unstructured":"Kekale M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adher 9:1733\u201340","journal-title":"Patient Prefer Adher"},{"key":"3286_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2014.991440","volume":"31","author":"MA Ward","year":"2015","unstructured":"Ward MA, Fang G, Richards KL et al (2015) Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin 31:289\u201397","journal-title":"Curr Med Res Opin"},{"key":"3286_CR17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","volume":"30","author":"A Guerin","year":"2014","unstructured":"Guerin A, Chen L, Dea K et al (2014) Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin 30:1345\u201352","journal-title":"Curr Med Res Opin"},{"key":"3286_CR18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA et al (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306\u201311","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3286-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:40:32Z","timestamp":1498318832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3286-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3286-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2016,6,3]]}}}